- Home
- IART vs TYRA Comparison
IART vs TYRA Comparison
Compare IART & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IART
- TYRA
- Stock Information
- Founded
- IART 1989
- TYRA 2018
- Country
- IART United States
- TYRA United States
- Employees
- IART N/A
- TYRA N/A
- Industry
- IART Medical/Dental Instruments
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- IART Health Care
- TYRA Health Care
- Exchange
- IART Nasdaq
- TYRA Nasdaq
- Market Cap
- IART 1.8B
- TYRA 812.7M
- IPO Year
- IART 1995
- TYRA 2021
- Fundamental
- Price
- IART $21.80
- TYRA $14.00
- Analyst Decision
- IART Hold
- TYRA Strong Buy
- Analyst Count
- IART 8
- TYRA 5
- Target Price
- IART $28.14
- TYRA $31.00
- AVG Volume (30 Days)
- IART 542.2K
- TYRA 218.5K
- Earning Date
- IART 11-04-2024
- TYRA 11-07-2024
- Dividend Yield
- IART N/A
- TYRA N/A
- EPS Growth
- IART N/A
- TYRA N/A
- EPS
- IART N/A
- TYRA N/A
- Revenue
- IART $1,564,920,000.00
- TYRA N/A
- Revenue This Year
- IART $6.71
- TYRA N/A
- Revenue Next Year
- IART $6.08
- TYRA N/A
- P/E Ratio
- IART N/A
- TYRA N/A
- Revenue Growth
- IART 1.45
- TYRA N/A
- 52 Week Low
- IART $16.81
- TYRA $11.24
- 52 Week High
- IART $45.42
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- IART 37.26
- TYRA 32.68
- Support Level
- IART $23.74
- TYRA $14.65
- Resistance Level
- IART $24.59
- TYRA $15.55
- Average True Range (ATR)
- IART 0.80
- TYRA 0.72
- MACD
- IART -0.41
- TYRA 0.02
- Stochastic Oscillator
- IART 13.35
- TYRA 3.12
About IART Integra LifeSciences Holdings Corporation
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).